Before you read. This page explains what the FDA label and the current multisociety perioperative guidance say. It is educational, it cannot assess your procedure or your health, and it is not a decision you should make alone. Whether to hold a GLP-1 medicine before a procedure is a decision for you, your prescriber, and the anaesthesia or endoscopy team together — the guidance says so explicitly. Do not stop or continue a prescribed medicine on the strength of a web page. Tell every team involved that you take it, and let them decide.
Quick answer
Two facts, and they point in slightly different directions.
The label does not tell you to stop. In October 2025 the shared Rybelsus and Ozempic tablets label added section 5.9, a warning about pulmonary aspiration during general anaesthesia or deep sedation. Read closely, it does something unusual: it states that the available data are insufficient to say whether holding the drug would help. What it instructs is one thing only — tell your healthcare providers before any planned surgery or procedure.
The guidance your surgeon follows does have a number, and for a daily tablet it is small. The 2024 multisociety perioperative guidance, affirmed by the American Society of Anesthesiologists, suggests that when a hold is judged necessary, daily formulations are held on the day of the procedure and weekly formulations for a week beforehand.
Almost everything written online about GLP-1 medicines and surgery is written about the weekly injection. If you have been told to stop a week early and you take a tablet every morning, that advice was built for a different medicine.
What section 5.9 actually says
It is worth reading in full, because the hedge in the middle is the part that gets dropped in summaries:
RYBELSUS and OZEMPIC tablets delay gastric emptying. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations. Available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking RYBELSUS or OZEMPIC tablets, including whether modifying preoperative fasting recommendations or temporarily discontinuing RYBELSUS or OZEMPIC tablets could reduce the incidence of retained gastric contents. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking RYBELSUS or OZEMPIC tablets.
Three things are being said at once.
The events are rare and they are postmarketing — reported after approval, not counted in a trial with a comparison group, which is why no rate appears anywhere in the section. The mechanism is real and is in the label's own pharmacology: these tablets delay gastric emptying. And the honest part, which regulators do not write often: nobody has shown that stopping the drug fixes it.
Note the specific phrase despite reported adherence to preoperative fasting recommendations. The concern is not that people ate breakfast. It is that some stomachs were not empty after the standard fast.
Delayed gastric emptying is the mechanism, and it is not a side effect
The slowing is not an adverse reaction that happens to some people. It is part of how the drug works.
The label's pharmacodynamics section describes a delay in gastric emptying in the early postprandial phase as one of the mechanisms by which semaglutide lowers blood glucose. Food leaves the stomach more slowly, glucose arrives in the bloodstream more slowly, and the post-meal peak is lower. The same property is a large part of why appetite falls.
So the perioperative question is not has this drug gone wrong. It is does a stomach that empties more slowly finish emptying inside a standard fasting window. For most people the answer appears to be yes; the reports exist because for some people it was no. For what the label does and does not attribute to the drug across the rest of the symptom list, we go through it symptom by symptom.
Why a week off a daily pill is not the same as a week off a weekly shot
This is the part that gets muddled, and the muddle has a simple cause.
Semaglutide's elimination half-life is approximately one week whether you swallow it or inject it. Stopping the tablet does not clear the drug from you quickly — the label states that semaglutide is present in the circulation for about five weeks after the last dose. On that measure, seven days off the tablet buys almost nothing that one day off does not.
What differs is the dosing interval. A weekly injection given on a Monday puts its whole dose in at once; skipping the next Monday means the level is falling by the time of a Thursday procedure. A daily tablet delivers a small amount each morning against a slowly accumulating background, and under 1% of each tablet is absorbed at all.
The guidance reflects that. Where a hold is judged necessary, the suggested duration for daily formulations is the day of the procedure. For weekly formulations it is a week. Same molecule, different arithmetic. The five-week tail after the last tablet covers what actually happens to the level when you stop.
| Weekly injection | Daily tablet | |
|---|---|---|
| Suggested hold, when a hold is judged necessary | About one week before | The day of the procedure |
| What one skipped dose changes | A whole week's dose | One morning's fraction of a dose |
| Elimination half-life | ~1 week | ~1 week |
| Time present in circulation after the last dose | About five weeks | About five weeks |
The bottom two rows are the same on purpose. Holding is not about clearing the drug. It is about the stomach on the day.
The guidance surgeons actually work from
In late 2024 a group of societies — gastroenterology, metabolic and bariatric surgery, perioperative care of patients with obesity, and gastrointestinal and endoscopic surgery — published joint clinical practice guidance, and the American Society of Anesthesiologists affirmed its value.
Its central move was to stop issuing a blanket instruction. The guidance is built around shared decision-making between the patient, the prescribing team, the proceduralist and the anaesthetist, weighed against the metabolic reason the drug was prescribed in the first place. Holding is conditional on an assessment of aspiration risk, not automatic.
That is a more useful framework than a rule, and it is also why you cannot resolve this by reading. The inputs are your dose, your phase, your symptoms, your other conditions and the procedure itself.
The five things that move the risk
The guidance names what raises the chance of retained gastric contents, and the list is specific enough to be worth carrying to an appointment:
- Being in the escalation phase rather than on a stable maintenance dose
- A higher dose
- Weekly dosing rather than daily
- Gastrointestinal symptoms — nausea, vomiting, abdominal pain, dyspepsia, constipation
- Comorbid conditions that delay gastric emptying, such as bowel dysmotility, gastroparesis or Parkinson's disease
Two of those are in your favour if you take a tablet: daily dosing is on the lower-risk side of the list, and the tablet ladder holds each step for 30 days, so people spend most of their time on a stable dose rather than climbing.
The one to take seriously is the third bullet from your own side of it. If you are currently having nausea or vomiting — and the label ties those to escalation weeks — that is not a detail to leave out of the pre-op call because it feels minor. It is one of the five inputs.
The pre-op questions are all dated questions: what dose, since when, any symptoms and when. Takely keeps the dose changes and the daily notes on one private timeline, so the answer is a screen rather than a reconstruction. Open Takely in your browser →
The 24-hour liquid diet, and where it comes from
Where there is concern about delayed gastric emptying, the guidance suggests preoperative diet modification: a liquid diet for at least 24 hours, the same approach already used before colonoscopy and bariatric surgery.
This is worth knowing because it is often the practical alternative to stopping the medicine. Rather than interrupting treatment for someone whose diabetes needs it, a team can empty the stomach the way they already know how to. If you are offered it, it is not an extra precaution invented for you — it is the standard prep, applied for a specific reason.
Colonoscopy and endoscopy specifically
Endoscopy is where much of the underlying evidence came from, because it is the setting in which somebody can look directly into a stomach and see whether it is empty.
The practical shape is the same as for surgery: the deciding factor is the level of sedation. A procedure under general anaesthesia or deep sedation is what section 5.9 addresses. Colonoscopy prep already involves a clear-liquid day, which is the mitigation the guidance suggests anyway — one reason colonoscopy is often less fraught here than a procedure with an ordinary overnight fast.
Tell the endoscopy unit when you book — not on the morning. Units differ in their local policy, and finding out at check-in is how procedures get cancelled.
What happens on the day
Three things, in the order a team is likely to reach for them.
Symptom assessment. The guidance is explicit that all patients should still be assessed on the day for symptoms suggesting delayed gastric emptying, whether or not the drug was held. Holding is not a substitute for asking.
Gastric ultrasound, where available. Point-of-care ultrasound can assess whether the stomach is empty. The guidance is candid about its limits: it depends on institutional resources, on operator variability, and on who is credentialled to do it. It is an option, not a standard.
If contents are found. The decision is then between a rapid sequence induction — an intubation technique intended to minimise aspiration risk — and postponing. That is an anaesthetic judgement, made in the room.
None of these requires anything from you except an accurate account of what you take and how you have been feeling.
Restarting, and the question the label does not answer
Here is a gap worth naming rather than papering over.
The label has one instruction about a missed tablet: if a dose is missed, skip it and take the next dose the following day. That sentence is about a single forgotten morning. It is not restart guidance after a planned hold, and the label does not offer any.
Neither does the perioperative guidance, which is focused on the period before the procedure. So when to resume — particularly after abdominal surgery, or while you are eating little, or if you are on a sulfonylurea or insulin whose doses were adjusted around the procedure — is a question for the team that prescribed it. Ask before you are discharged, while there is still someone to ask.
For what a single skipped morning does to the level in your blood, we cover the arithmetic separately. The short version is that it is a small dent in a slow curve, which is exactly why a one-day hold is a modest thing to ask of a treatment.
What to tell the team, and when
Say it at booking, and say it again at the pre-op assessment — the two conversations are usually held by different people. The sentence that contains everything they need:
"I take semaglutide tablets — [Rybelsus or Ozempic tablets], [dose] mg once daily. My last dose increase was [date]. In the past week I have had [no gastrointestinal symptoms / nausea on these days / vomiting on these days]."
Dose, phase, symptoms, dates. Those are four of the five risk inputs, and you are the only person who has them. A dated log of your dose changes turns that from a memory exercise into a read-out.
One more thing, easy to forget: the tablet's own morning rule still applies on any day you take it. Nothing but plain water, up to 4 ounces, and 30 minutes before anything else. On a fasting morning that is usually straightforward — but if you have been told nil by mouth, the tablet is not exempt from that instruction, and it is a question for the team rather than a judgement call at 6am.
Frequently asked questions
Do I have to stop Rybelsus before surgery?
The label does not say to. It states that available data are insufficient to say whether temporarily discontinuing would reduce retained gastric contents, and instructs patients to inform their healthcare providers before any planned surgery or procedure. The 2024 multisociety guidance treats holding as a shared decision based on aspiration risk, and where a hold is judged necessary it suggests daily formulations be held on the day of the procedure.
How long before surgery should I stop the semaglutide tablet?
That is not a decision to make from a web page, and the answer differs by procedure and by person. What the guidance suggests, when a hold is indicated, is the day of the procedure for daily formulations and a week for weekly formulations. Take that to your team rather than acting on it.
Do I need to stop Rybelsus before a colonoscopy?
Ask the endoscopy unit when you book. Colonoscopy already involves a clear-liquid preparation day, which is the same mitigation the guidance suggests for delayed gastric emptying, so local policy varies. The deciding factor is generally the depth of sedation planned.
Why does my surgeon say a week and my label say nothing?
Because most perioperative advice was written around weekly GLP-1 injections, where a week's hold means skipping an entire dose. On a daily tablet the same seven days skips seven small fractions against a background that takes about five weeks to clear. If your team's instruction was given for a weekly injection, it is worth checking that they know you take a tablet.
Is the aspiration risk large?
The label describes the reports as rare and as postmarketing, meaning they were reported after approval rather than counted in a controlled trial, so no rate can be quoted from them. The reason it is treated seriously despite being rare is the consequence rather than the frequency.
Should I stop taking it because of this warning?
No — not on your own. The medicine is treating something. The guidance frames every one of these decisions as balancing procedural safety against the metabolic reason for the prescription, which is exactly the balance an individual cannot strike alone.
Primary sources and further reading
- FDA Prescribing Information — RYBELSUS (semaglutide) tablets and OZEMPIC (semaglutide) tablets, sections 2.1, 5.9, 12.2 and 12.3 (revised 10/2025 and 12/2025) ↗
- Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period (2024) ↗
- American Society of Anesthesiologists — consensus-based guidance on preoperative management of patients on GLP-1 receptor agonists ↗
Label sections and society guidance both change. Everything on this page was checked against those sources on 8 September 2026, and the label revision dates above are the ones printed on the document we read.